120 related articles for article (PubMed ID: 32933914)
1. Cytokine storm and use of anakinra in a patient with COVID-19.
Nemchand P; Tahir H; Mediwake R; Lee J
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32933914
[TBL] [Abstract][Full Text] [Related]
2. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
3. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
Bilia S; Giannini D; Rizzelli GML; Tavoni A
Clin Exp Rheumatol; 2020; 38(3):579. PubMed ID: 32456767
[No Abstract] [Full Text] [Related]
4. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Castelli V; Cimini A; Ferri C
Front Immunol; 2020; 11():2132. PubMed ID: 32983172
[TBL] [Abstract][Full Text] [Related]
5. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):18951-18953. PubMed ID: 32699149
[TBL] [Abstract][Full Text] [Related]
6. Use of anakinra in severe COVID-19: A case report.
Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
[TBL] [Abstract][Full Text] [Related]
7. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
Aouba A; Baldolli A; Geffray L; Verdon R; Bergot E; Martin-Silva N; Justet A
Ann Rheum Dis; 2020 Oct; 79(10):1381-1382. PubMed ID: 32376597
[No Abstract] [Full Text] [Related]
8. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.
González-García A; García-Sánchez I; Lopes V; Moreno-Arrones OM; Tortosa-Cabañas M; Elías-Sáenz I; Hernández-Rodríguez J
Rheumatology (Oxford); 2020 Aug; 59(8):2171-2173. PubMed ID: 32568376
[No Abstract] [Full Text] [Related]
9. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
Wilson JG; Simpson LJ; Ferreira AM; Rustagi A; Roque J; Asuni A; Ranganath T; Grant PM; Subramanian A; Rosenberg-Hasson Y; Maecker HT; Holmes SP; Levitt JE; Blish CA; Rogers AJ
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32706339
[TBL] [Abstract][Full Text] [Related]
10. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.
Steinhardt MJ; Wiebecke S; Weismann D; Frantz S; Tony HP; Klinker H; Schmalzing M
Scand J Rheumatol; 2020 Sep; 49(5):414-416. PubMed ID: 32914670
[No Abstract] [Full Text] [Related]
11. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
Front Immunol; 2020; 11():1708. PubMed ID: 32754163
[TBL] [Abstract][Full Text] [Related]
12. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
13. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
14. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
Loganathan S; Athalye SN; Joshi SR
Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
[TBL] [Abstract][Full Text] [Related]
15. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.
Dimopoulos G; de Mast Q; Markou N; Theodorakopoulou M; Komnos A; Mouktaroudi M; Netea MG; Spyridopoulos T; Verheggen RJ; Hoogerwerf J; Lachana A; van de Veerdonk FL; Giamarellos-Bourboulis EJ
Cell Host Microbe; 2020 Jul; 28(1):117-123.e1. PubMed ID: 32411313
[TBL] [Abstract][Full Text] [Related]
16. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.
Imazio M; Brucato A; Lazaros G; Andreis A; Scarsi M; Klein A; De Ferrari GM; Adler Y
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):625-629. PubMed ID: 32658005
[TBL] [Abstract][Full Text] [Related]
19. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322
[TBL] [Abstract][Full Text] [Related]
20. The Management of Cytokine Storm in COVID-19.
Rumende CM; Susanto EC; Sitorus TP
Acta Med Indones; 2020 Jul; 52(3):306-313. PubMed ID: 33020343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
